Ultime prove

EudraCT Number: 2022-003885-19

Sponsor Protocol Number: NOT-APPLICABLE-HUFA

Start Date: 2023-03-15

Sponsor Name:

Full Title: ECOGUIDED GENICULAR NERVE BLOCK IN PATIENTS WITH KNEE OSTEOARTHRITIS BY LOCAL ANESTHETIC OR BY COMBINATION OF LOCAL ANESTHETIC AND CORTICOID: PLACEBO-CONTROLLED RANDOMIZED BLIND CLINICAL TRIAL

Medical condition: KNEE OSTEOARTHRITIS

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002593-89

Sponsor Protocol Number: TV48574-IMM-20038

Start Date: 2023-03-15

Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.

Full Title: A 24-Week, Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcera...

Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004856	10045365	Ulcerative colitis	LLT
	20.0	100000004856	10011400	Crohn's colitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004890-29

Sponsor Protocol Number: FIT-PIV

Start Date: 2023-03-09

Sponsor Name: Elgan Pharma Ltd

Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004856	10025479	Malabsorption syndrome	LLT

Population Age: Preterm newborn infants, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005066-17

Sponsor Protocol Number: CADPT09A12201

Start Date: 2023-03-07

Sponsor Name: Novartis Pharma AG

Full Title: A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants w...

Medical condition: Idiopathic pulmonary fibrosis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10021240	Idiopathic pulmonary fibrosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001384-27

Sponsor Protocol Number: 2022-031

Start Date: 2023-02-28

Sponsor Name: Franciscus Gasthuis & Vlietland

Full Title: Peroperative Administration of Tranexamic acid in Roux-en-Y and one-anastomosis gastric bypass to reduce hemorrhage rates (PATRY study): a randomized controlled trial

Medical condition: Morbid obesity

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004865	10059610	Obesity surgery	LLT
	21.0	100000004861	10027966	Morbid obesity	LLT
	21.1	100000004865	10068900	Bariatric surgery	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002833-33

Sponsor Protocol Number: APL2-C3G-314

Start Date: 2023-02-22

Sponsor Name: Apellis Pharmaceuticals, Inc.

Full Title: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferati...

Medical condition: C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10038359 - Renal and urinary disorders	10038359	Renal and urinary disorders	SOC
	20.0	10038359 - Renal and urinary disorders	10077827	C3 glomerulopathy	PT
	21.1	10038359 - Renal and urinary disorders	10027168	Membranoproliferative glomerulonephritis	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005528-39

Sponsor Protocol Number: 78934804UCO2001

Start Date: 2023-02-16

Sponsor Name: Janssen-Cilag International NV

Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...

Medical condition: Moderately to Severely Active Ulcerative Colitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004856	10045365	Ulcerative colitis	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing) CZ (Ongoing) NL (Ongoing) SK (Ongoing) BG (Ongoing) DK (Ongoing) SE (Ongoing) SI (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003063-21

Sponsor Protocol Number: ENX-CL-04-002a

Start Date: 2023-02-14

Sponsor Name: Enlivex Therapeutics RDO, Ltd.

Full Title: A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination with Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Medical condition: Advanced Solid Tumor Malignancy

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10065147	Malignant solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-002326-24

Sponsor Protocol Number: ALKS4230-007

Start Date: 2023-02-13

Sponsor Name: Alkermes, Inc.

Full Title: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial O...

Medical condition: Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	20.1	10022891 - Investigations	10080244	Peritoneal cancer index	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Ongoing) ES (Ongoing) AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002691-36

Sponsor Protocol Number: CVAY736F12301

Start Date: 2023-02-07

Sponsor Name: Novartis Pharma AG

Full Title: A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therap...

Medical condition: Systemic Lupus Erythematosus

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10042945	Systemic lupus erythematosus	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Ongoing) HU (Ongoing) ES (Ongoing) CZ (Ongoing)

Trial results: (No results available)

Ultime prove

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici